Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Multiple Myeloma Post-Allogeneic Transplant
NCT00504634Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2004
- Primary completion
- Aug 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00504634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504634.